Teva’s Neopogen biosimilar=Tbo-filgrastim approved: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm317392.htm Already in the market in EU (Tevagrastim), will not enter the US market before November 2013 (settlement with Amgen).